
MergerNov 20, 2026, 05:01 PM
BEACON TOPCO, INC. Completes Merger with Clywedog Therapeutics
AI Summary
BEACON TOPCO, INC. (CLYD) announced the consummation of its merger with Clywedog Therapeutics, Inc. on November 20, 2026. This transaction, along with a prior acquisition of Barinthus Biotherapeutics plc, results in BEACON TOPCO, INC. becoming the successor issuer to Barinthus Bio under Rule 12g-3(a) of the Exchange Act. The company also released its unaudited condensed consolidated financial statements for the periods ending June 30, 2026, showing a net loss of $12,996,193 for the six months ended June 30, 2026.
Key Highlights
- BEACON TOPCO, INC. (formerly Beacon Topco, Inc.) consummated a merger with Clywedog Therapeutics, Inc. on November 20, 2026, becoming the successor issuer to Barinthus Bio.
- The company reported a net loss of $12,996,193 for the six months ended June 30, 2026.
- Total assets for Clywedog Therapeutics, Inc. were $2,918,892 as of June 30, 2026.
- Total liabilities for Clywedog Therapeutics, Inc. were $39,196,085 as of June 30, 2026.
- Research and development expenses for the six months ended June 30, 2026, totaled $11,746,175.
- The company had cash of $68,997 as of June 30, 2026.
Price Impact
More from CLYD